The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Allison Betof Warner
Consulting or Advisory Role - Adaptimmune; BluePath Solutions; Bristol-Myers Squibb/Medarex; immatics; IO Biotech; Iovance Biotherapeutics; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Iovance Biotherapeutics (Inst); Lyell Immunopharma (Inst); Obsid (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Regeneron; SERVIER; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Krystal Biotech (Inst); Macrogenics (Inst); Nested Therapeutics (Inst); Pierre Fabre (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - immatics
 
Adi Diab
Honoraria - Cullinan Oncology (Inst); CureVac; CytomX Therapeutics; Genesis Therapeutics; Idera (Inst); Lytix Biopharma (Inst); Memgen; Nektar (Inst); Pfizer; Regeneron; Teva
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Cullinan Oncology (Inst); Cullinan Oncology (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
 
Christoffer Gebhardt
Stock and Other Ownership Interests - Dermagnostix; Dermagnostix R&D
Honoraria - BMS GmbH & Co. KG; Delcath Systems; Immunocore; Medscape; MSD; Novartis; Onkowissen; Pierre Fabre; Regeneron; Sanofi
Consulting or Advisory Role - BioNTech; BMS GmbH & Co. KG; Delcath Systems; Immatics; Immunocore; Iovance Biotherapeutics; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi; Skyline Diagnostics; Sun Pharma; Sysmex
Speakers' Bureau - BMS GmbH & Co. KG; Delcath Systems; Immunocore; MSD; Novartis; Pierre Fabre; Sun Pharma
Research Funding - BMS GmbH & Co. KG (Inst); Novartis (Inst); Pierre Fabre (Inst); Regeneron (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Pierre Fabre; Sun Pharma
 
Leonel Hernandez-Aya
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Massive Bio; Replimune; Replimune
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); immatics (Inst); immatics (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); Polynoma (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Castle Biosciences; Sanofi/Regeneron
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen; Cardinal Health; Delcath Systems; Endeavor BioMedicines; Immunocore; Replimune
 
Lilit Karapetyan
Travel, Accommodations, Expenses - immatics
 
Donald Lawrence
No Relationships to Disclose
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Tara Mitchell
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
 
Stergios Moschos
Research Funding - Amgen (Inst); Syndax
 
Justin Moser
Honoraria - Caris Life Sciences; Curio Science; Daiichi Sankyo; Horizon CME; TGen
Consulting or Advisory Role - Adagene; Amunix; BMS GmbH & Co. KG; Boxer Capital; Genome Insight; Imaging Endpoints; Incyte; Iovance Biotherapeutics; IQVIA; Novotech; Oberland Capital; Pfizer; Red Arrow Therapeutics; Replimune; Thirona Biosciences; Vilya; Werewolf Therapeutics (Inst)
Speakers' Bureau - Caris Life Sciences; Castle Biosciences; Immunocare Therapies
Research Funding - Adaptimmune (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); BioEclipse Therapeutics (Inst); Bright Peak Therapeutics (Inst); Fate Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); IDEAYA Biosciences (Inst); Immatics (Inst); ImmuneSensor Therapeutics (Inst); Iovance Biotherapeutics (Inst); ISTARI Oncology (Inst); Nektar (Inst); Novocure (Inst); Orionis Biosciences (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Spark Therapeutics (Inst); Storm Therapeutics (Inst); Synthorx (Inst); Trishula Therapeutics (Inst); TScan Therapeutics (Inst); University of Arizona (Inst); Werewolf Therapeutics (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - US PCT/US24/27766
Other Relationship - Caris Life Sciences
 
Anthony Olszanski
Consulting or Advisory Role - Anaveon; Bristol-Myers Squibb; IO Biotech; Oncosec; Pfizer; Replimune; Signatera
Research Funding - Anaveon (Inst); Antengene (Inst); Clasp (Inst); Eutilex (Inst); GlaxoSmithKline (Inst); Lantern Pharma (Inst); Perspectives (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Shionogi (Inst); Tagworks (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Pfizer; Takeda
 
Sapna Patel
Honoraria - Cedars Sinai; Clinical Care Options; Clinical Education Alliance (Inst); Emory University; OncLive/MJH Life Sciences; Paradigm; University of Michigan; Vindico Medical Education (Inst)
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; IDEAYA Biosciences; immatics; IO Biotech; MSD; Novartis; Obsidian Therapeutics; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; Melanoma Research Alliance (MRA); Melanoma Research Foundation; MSD; SITC/ACCC; SWOG; TriSalus Life Sciences
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Agenus (Inst); Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
James Smithy
Consulting or Advisory Role - Bristol-Myers Squibb; IO Biotech; Iovance Biotherapeutics
Research Funding - Daiichi Sankyo (Inst); IO Biotech (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Immatics
 
Thach-Giao Truong
Consulting or Advisory Role - Iovance Biotherapeutics; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Castle Biosciences (Inst); Erasca, Inc (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis; Perspective Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
 
Martin Wermke
Honoraria - Amgen; BMS GmbH & Co. KG; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; Pfizer; SYNLAB
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis; PharmaMar; Regeneron; Tacalyx; Zymeworks
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GEMoaB; immatics; Iovance Biotherapeutics; Janssen Oncology; Merck Serono; Pfizer; Sanofi/Aventis
 
Cedrik Britten
Employment - Immatics
Leadership - Immatics
Stock and Other Ownership Interests - Immatics